Corticosteroid use and incident myocardial infarction in adults hospitalized for community-acquired pneumonia

Annals of the American Thoracic Society

Volumn 16, Issue 1, 2019, Pages 91-98

  Cangemi, Roberto ^a   Falcone, Marco ^a   Taliani, Gloria ^a   Calvieri, Camilla ^a   Tiseo, Giusy ^a   Romiti, Giulio Francesco ^a   Bertazzoni, Giuliano ^b   Farcomeni, Alessio ^a   Violi, Francesco ^a   Battaglia, Simona ^a   Biliotti, Elisa ^a   Calabrese, Cinzia Myriam ^a   Celestini, Andrea ^a   Casciaro, Marco ^a   De Angelis, Maurizio ^a   Di Diego, Ilaria ^a   De Marzio, Paolo ^a   Esvan, Rozenn ^a   Ferraro, Giovanni ^a   Sulekova, Lucia Fontanelli ^a   Franchi, Cristiana ^a   Giordo, Laura ^a   Khoury, Fuad ^a   Morelli, Sergio ^a   Catassi, Giulia Naspi ^a   Palange, Paolo ^c   Pastori, Daniele ^a   Prosperi, Anna ^a   Raparelli, Valeria ^a   Capparuccia, Marco Rivano ^a   Rossi, Elisabetta ^a   Scarpellini, Maria Gabriella ^a   Trapè, Stefano ^a   Toriello, Filippo ^a   Vano, Marco ^a   Venditti, Mario ^c   more..

^a Department of Internal Medicine and Medical Specialties ^*  (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Corticosteroids; Myocardial infarction; Pneumonia

Indexed keywords

BETAMETHASONE; CORTICOSTEROID; METHYLPREDNISOLONE; PREDNISONE;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMMUNITY ACQUIRED PNEUMONIA; FEMALE; HEART INFARCTION; HOSPITALIZATION; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; COMMUNITY ACQUIRED INFECTION; COMPLICATION; EPIDEMIOLOGY; HOSPITAL MORTALITY; INCIDENCE; KAPLAN MEIER METHOD; MIDDLE AGED; PNEUMONIA; RISK FACTOR; VERY ELDERLY;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HOSPITAL MORTALITY; HUMANS; INCIDENCE; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PNEUMONIA; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 85059227201     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201806-419OC     Document Type: Article

References (41)

1. Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 2013;68:1057–1065.
2. Violi F, Cangemi R, Falcone M, Taliani G, Pieralli F, Vannucchi V, et al.; SIXTUS (Thrombosis-Related Extrapulmonary Outcomes in Pneumonia) Study Group. Cardiovascular complications and short-term mortality risk in community-acquired pneumonia. Clin Infect Dis 2017;64:1486–1493.
3. Cangemi R, Calvieri C, Falcone M, Bucci T, Bertazzoni G, Scarpellini MG, et al.; SIXTUS Study Group. Relation of cardiac complications in the early phase of community-acquired pneumonia to long-term mortality and cardiovascular events. Am J Cardiol 2015;116:647–651.
4. Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, Fine MJ. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 2012;125:773–781.
5. Feldman C, Anderson R. Corticosteroids in the adjunctive therapy of community-acquired pneumonia: an appraisal of recent meta-analyses of clinical trials. J Thorac Dis 2016;8:E162–E171.
6. Wan YD, Sun TW, Liu ZQ, Zhang SG, Wang LX, Kan QC. Efficacy and safety of corticosteroids for community-acquired pneumonia: a systematic review and meta-analysis. Chest 2016;149: 209–219.
7. Stern A, Skalsky K, Avni T, Carrara E, Leibovici L, Paul M. Corticosteroids for pneumonia. Cochrane Database Syst Rev 2017;12:CD007720.
8. Cangemi R, Casciaro M, Rossi E, Calvieri C, Bucci T, Calabrese CM, et al.; SIXTUS Study Group; SIXTUS Study Group. Platelet activation is associated with myocardial infarction in patients with pneumonia. J Am Coll Cardiol 2014;64:1917–1925.
9. Cangemi R, Pignatelli P, Carnevale R, Bartimoccia S, Nocella C, Falcone M, et al.; SIXTUS Study Group. Low-grade endotoxemia, gut permeability and platelet activation in community-acquired pneumonia. J Infect 2016; 73:107–114.
10. Moraes LA, Paul-Clark MJ, Rickman A, Flower RJ, Goulding NJ, Perretti M. Ligand-specific glucocorticoid receptor activation in human platelets. Blood 2005;106:4167–4175.
11. Liverani E, Banerjee S, Roberts W, Naseem KM, Perretti M. Prednisolone exerts exquisite inhibitory properties on platelet functions. Biochem Pharmacol 2012;83:1364–1373.
12. van Giezen JJ, Brakkee JG, Dreteler GH, Bouma BN, Jansen JW. Dexamethasone affects platelet aggregation and fibrinolytic activity in rats at different doses which is reflected by their effect on arterial thrombosis. Blood Coagul Fibrinolysis 1994;5:249–255.
13. Glass F, Lippton H, Kadowitz PJ. Effects of methylprednisolone and hydrocortisone on aggregation of rabbit platelets induced by arachidonic acid and other aggregating substances. Thromb Haemost 1981;46:676–679.
14. Cangemi R, Carnevale R, Nocella C, Calvieri C, Cammisotto V, Castellani V, et al. Glucocorticoids impair platelet thromboxane biosynthesis in community-acquired pneumonia. Pharmacol Res 2018;131:66–74.
15. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015;372:1114–1125.
16. Falcone M, Venditti M, Shindo Y, Kollef MH. Healthcare-associated pneumonia: diagnostic criteria and distinction from community-acquired pneumonia. Int J Infect Dis 2011;15:e545–e550.
17. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243–250.
18. Falcone M, Corrao S, Venditti M, Serra P, Licata G. Performance of PSI, CURB-65, and SCAP scores in predicting the outcome of patients with community-acquired and healthcare-associated pneumonia. Intern Emerg Med 2011;6:431–436.
19. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al.; European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33: 1635–1701.
20. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 report: GOLD executive summary. Am J Respir Crit Care Med 2017;195:557–582.
21. Loffredo L, Carnevale R, Cangemi R, Angelico F, Augelletti T, Di Santo S, et al. NOX2 up-regulation is associated with artery dysfunction in patients with peripheral artery disease. Int J Cardiol 2013;165:184–192.
22. Cangemi R, Celestini A, Calvieri C, Carnevale R, Pastori D, Nocella C, et al. Different behaviour of NOX2 activation in patients with paroxysmal/ persistent or permanent atrial fibrillation. Heart 2012;98:1063–1066.
23. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al.; WRITING COMMITTEE MEMBERS; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:e240–e327.
24. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al.; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Circulation 2012;126:2020–2035.
25. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al.; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:2160–2236.
26. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:801–810.
27. Corrales-Medina VF, Musher DM, Shachkina S, Chirinos JA. Acute pneumonia and the cardiovascular system. Lancet 2013;381:496–505.
28. Violi F, Cangemi R, Calvieri C. Pneumonia, thrombosis and vascular disease. J Thromb Haemost 2014;12:1391–1400.
29. Cangemi R, Della Valle P, Calvieri C, Taliani G, Ferroni P, Falcone M, et al.; SIXTUS Study Group. Low-grade endotoxemia and clotting activation in the early phase of pneumonia. Respirology 2016;21: 1465–1471.
30. FitzGerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991;68: 11B–15B.
31. Santos-Gallego CG, Badimon JJ. The sum of two evils: pneumonia and myocardial infarction: is platelet activation the missing link? J Am Coll Cardiol 2014;64:1926–1928.
32. Loffredo L, Cangemi R, Perri L, Catasca E, Calvieri C, Carnevale R, et al.; SIXTUS study group; SIXTUS (thromboSIs-related eXTra-pulmonary oUtcomeS in pneumonia) study group. Impaired flow-mediated dilation in hospitalized patients with community-acquired pneumonia. Eur J Intern Med 2016;36:74–80.
33. Versaci F, Gaspardone A, Tomai F, Ribichini F, Russo P, Proietti I, et al.; Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation Study. Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol 2002;40:1935–1942.
34. Ribichini F, Tomai F, De Luca G, Boccuzzi G, Presbitero P, Pesarini G, et al.; CEREA-DES investigators. Immunosuppressive therapy with oral prednisone to prevent restenosis after PCI: a multicenter randomized trial. Am J Med 2011;124:434–443.
35. Sardar P, Chatterjee S, Mukherjee D, Garratt KN. Steroids for the prevention of restenosis in bare-metal stents—a systematic review and meta-analysis. J Invasive Cardiol 2012;24:98–103.
36. Bergström I, Lundberg AK, Jönsson S, Särndahl E, Ernerudh J, Jonasson L. Annexin A1 in blood mononuclear cells from patients with coronary artery disease: Its association with inflammatory status and glucocorticoid sensitivity. PLoS One 2017;12:e0174177.
37. Molinos L, Clemente MG, Miranda B, Alvarez C, del Busto B, Cocina BR, et al.; ASTURPAR Group. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect 2009;58:417–424.
38. Liapikou A, Polverino E, Ewig S, Cillóniz C, Marcos MA, Mensa J, et al. Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients. Eur Respir J 2012;39:855–861.
39. Gómez-Junyent J, Garcia-Vidal C, Viasus D, Millat-Martínez P, Simonetti A, Santos MS, et al. Clinical features, etiology and outcomes of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. PLoS One 2014;9:e105854.
40. Praticò D, Basili S, Vieri M, Cordova C, Violi F, Fitzgerald GA. Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2a-III, an index of oxidant stress. Am J Respir Crit Care Med 1998;158:1709–1714.
41. Davì G, Basili S, Vieri M, Cipollone F, Santarone S, Alessandri C, et al.; The Chronic Obstructive Bronchitis and Haemostasis Study Group. Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;156: 1794–1799.